Singh Chauhan Rajeev, Saxena Ravinder Kumar, Varshey Saurabh
Department of ENT, Nepalgunj Medical College, Kohalpur, Nepalgunj, Nepal.
Ear Nose Throat J. 2011 May;90(5):218-22. doi: 10.1177/014556131109000506.
In monitoring patients for drug-induced hearing loss, most audiometric evaluations are limited to the range of frequencies from 0.25 to 8 kHz. However, such testing would fail to detect ototoxicity in patients who have already experienced hearing loss in the ultrahigh frequencies from 10 to 20 kHz. Awareness of ultrahigh-frequency ototoxicity could lead to changes in a drug regimen to prevent further damage. We conducted a prospective study of 105 patients who were receiving a potentially ototoxic drug-either gentamicin, amikacin, or cisplatin-to assess the value of ultrahigh-frequency audiometry in detecting systemic drug-induced hearing loss. We found that expanding audiometry into the ultrahigh-frequency range led to the detection of a substantial number of cases of hearing loss that would have otherwise been missed.
在监测患者药物性听力损失时，大多数听力测定评估仅限于0.25至8千赫的频率范围。然而，这种测试无法检测出在10至20千赫超高频范围内已经出现听力损失的患者的耳毒性。认识到超高频耳毒性可能会导致药物治疗方案的改变，以防止进一步损害。我们对105名正在接受可能具有耳毒性药物（庆大霉素、阿米卡星或顺铂）治疗的患者进行了一项前瞻性研究，以评估超高频听力测定在检测全身性药物性听力损失中的价值。我们发现，将听力测定扩展到超高频范围能够检测出大量原本会被漏诊的听力损失病例。
